Bernzott Capital Buys Another $3 Million of Silgan Stock Amid 20% Dip

Bernzott Capital Advisors disclosed a purchase of 71,353 Silgan Holdings (SLGN) shares in Q4 2025 (estimated $2.90M using average quarterly price), bringing its quarter-end stake to 203,262 shares worth $8.21M, or 3.9% of its 13F AUM and making Silgan a top-three holding. Silgan is trading at $43.19 (Feb. 2, 2026), with a $4.73B market cap, TTM revenue of $6.43B and TTM net income of $315.27M; the firm has recently underperformed (≈-20% y/y) after lowering 2025 guidance, but trades at ~12x forward earnings and EV/EBITDA ~9. Bernzott’s buy-the-dip posture, plus Silgan’s acquisition strategy (e.g., Weener) and steady dividend/net-income growth, suggests investor positioning toward a value/recovery thesis rather than signaling broad market-moving news.

Analysis

Market structure: Bernzott’s buy signals conviction that scale players in rigid packaging (SLGN) will capture share as weaker peers retrench. Silgan trades at ~12x forward P/E and EV/EBITDA ~9 after a ~20% YTD decline, implying the market is pricing near-term cyclical downside rather than structural impairment; large CPG customers and tuck-in M&A are the direct beneficiaries while small independent converters are most at risk.

Risk assessment: Near-term risks are a 10–20% downside if consumer staples volumes fall another 3–5% or if raw-material spreads (aluminum/steel) jump >10% without pass-through; low-probability tails include major plant outages, anti-plastic/packaging regulation or a failed integration of Weener that could push net leverage >3.0x. Immediate (days) moves will be flow-driven, 1–3 month risk centers are Q1 guidance and commodity moves, and 12–36 month outcomes depend on successful tuck-ins and margin recovery of 300–500bps.

Trade implications: Constructive but phased exposure — cheap valuation widens asymmetric upside if demand stabilizes; credit markets should tighten modestly if margins rebound, supporting bonds. Use directional equity sized conservatively and options to monetize entry — implied vols are elevated around earnings and can be harvested with spreads or put-selling to improve yield while capping downside.

Contrarian angles: Consensus frames SLGN as a cyclical dip; that understates durability from long-term CPG contracts and M&A optionality (Weener healthcare lift). Overdone fears: a continued multiple compression below EV/EBITDA 8 would be a tactical buying zone; conversely, complacency about integration and regulatory packaging shifts are underpriced risks.

Key Decisions for Investors

• Establish a phased long in SLGN totaling 2–3% portfolio NAV: buy 1% at market, add 1–2% if SLGN < $38 (≈12% below $43.19) or EV/EBITDA drops below 8.5; target holding horizon 12–24 months and target exit range $55–65 (≈27–51% upside) or exit if forward margin guidance is cut by >200bps.
• Sell 90-day cash-secured puts on SLGN at $38 strike size equal to 0.5–1% NAV to collect premium and set a worst-case acquisition basis ≈$36–$37; adjust if put implied vol rises >20% vs 30‑day realized vol.
• Pair trade: long SLGN vs short Sonoco (SON) 1:1 notional (or similar packaging peer) to express relative-scale recovery — establish over 2–4 weeks, target outperformance of 300–500bps in ROIC within 12 months, tighten if Silgan misses two consecutive quarters of margin recovery.
• Rotate 1–2% of portfolio from consumer cyclical exposure (e.g., XLY/selected retailers) into industrial staples/packaging ETFs or direct names (SLGN, SON) over 6–8 weeks to capitalize on lower valuations and defensive cash flows; rebalance if CPI-backed consumer demand drops >0.5% month-over-month.